炎症性肠病肠道纤维化的病理生理、诊断与管理挑战
肠道纤维化是炎症性肠病(IBD)的常见并发症,通常由慢性炎症导致。现有抗炎治疗对克罗恩病(CD)肠道纤维化影响甚微,但靶向纤维化通路的疗法带来希望。2018年IOIBD在阿姆斯特丹举办研讨会,综述了肠道纤维化的生物学背景、诊断、治疗及临床试验终点,重点讨论了抗纤维化治疗的试验设计。
要点
- 肠道纤维化是IBD常见并发症,通常由慢性炎症导致。
- 现有抗炎治疗对CD肠道纤维化影响甚微。
- 靶向纤维化通路的疗法对未来具有希望。
核心结论
- 肠道纤维化是IBD常见并发症,现有抗炎治疗对CD纤维化影响甚微,但靶向纤维化通路的疗法带来希望。
- 关键挑战之一是如何在临床试验和药物审批中定义和测量肠道纤维化的减少或逆转。
研究设计与样本
- 基础与临床科学家讨论了肠道纤维化的病理生理、狭窄型CD的生物标志物和影像学现状及近期临床研究。
主要发现
- IBD领域外研究者介绍了皮肤、肝和肺等其他器官纤维化过程的理解进展。
- 讨论了IBD抗纤维化治疗的临床试验设计,优先关注患者人群、患者报告结局(PROs)和影像学。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD) that is usually the consequence of chronic inflammation. Although the currently available anti-inflammatory therapies have had little impact on intestinal fibrosis in Crohn’s disease (CD), increased understanding of the pathophysiology and the development of therapies targeting fibrogenic pathways hold promise for the future. One of the critical challenges is how reduction or reversal of intestinal fibrosis should be defined and measured in the setting of clinical trials and drug approval. The International Organization for Inflammatory Bowel Disease (IOIBD) organized a workshop in Amsterdam, The Netherlands, on December 19th and 20th, 2018 in an attempt to review the current knowledge of the biological background, diagnosis, treatment of intestinal fibrosis and clinical trial endpoints. Basic and clinical scientists discussed the pathophysiology of intestinal fibrosis, the current status of biomarkers and imaging modalities in stenosing CD, and recent clinical studies in this area. Researchers from outside of the IBD field presented advances in the understanding of fibrotic processes in other organs, such as the skin, liver and lungs. Lastly, the design of clinical trials with antifibrotic therapy for IBD was discussed, with priority on patient populations, patient reported outcomes (PROs) and imaging. This report summarizes the key findings, discussions and conclusions of the workshop.
引用
- D'Haens G, Rieder F, Feagan BG, et al. Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. Gastroenterology. 2019. PMID: 31254502. doi:10.1053/j.gastro.2019.05.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。